SiSaf Ltd
Flavia M. Sutera is the current Head of Preclinical Development at SiSaf Ltd. Flavia M. specializes in the design and development of non-viral vectors for gene therapy applications. Flavia has previous experience as an R&D Team Leader, Postdoctoral Research Scientist, and Research Assistant at various institutions working on drug delivery systems and chemical synthesis studies. Flavia M. holds a PhD in Experimental Medicine and Neuroscience from the University of Palermo and a Master's degree in Chemistry and Pharmaceutical Technologies.
This person is not in any teams
This person is not in any offices
SiSaf Ltd
SiSaf is an RNA delivery and therapeutics company. Its proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon.The company’s Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improvethe stability, safety, and transfection efficiency of RNA. SiSaf uses sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and is maximizing the potential of its technology through research partnerships.Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, it has fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.